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Following publication of the original article \[[@CR1]\], the author reported that some values in Tables [2](#Tab1){ref-type="table"}, [3](#Tab2){ref-type="table"}, [4](#Tab3){ref-type="table"}, [5](#Tab4){ref-type="table"} and [6](#Tab5){ref-type="table"}. The correct Tables are as given below:Table 2reports the prevalence of cervical abnormalities observed in the sample (*N* = 599)Cytological statusn% of FSW (95%CI)Normal cytology51285.5% (82.4--88.2)ASC-US101.7% (0.8--3.04)LSIL6310.5% (8.2--13.3)HSIL142.3% (12.8--3.9)Excluded samples due to poor cell quality172.8%Table 3reports the prevalence of each HPV genotypes and STIspHR/ HR HPV GenotypeFrequency (n)PercentageHPV 16 (*N* = 616)9916.1%HPV 18 (*N* = 616)6811.0%HPV 31 (*N* = 616)498.0%HPV 33 (*N* = 616)20.3%HPV 35 (*N* = 616)7011.4%HPV 39 (*N* = 616)487.8%HPV 51 (*N* = 615)528.5%HPV 53 (*N* = 616)6811.0%HPV 56 (*N* = 616)457.3%HPV 58 (*N* = 616)304.9%HPV 59 (*N* = 616)7512.2%HPV 66 (*N* = 616)609.7%HPV 68 (*N* = 616)91.5%BV and STIs BV\* (*N* = 555)26848.3% TV (*N* = 609)19131.4% Candida (*N* = 609)12119.9%Table 4reports the prevalence of each HPV genotype among HPV-positive women with abnormal cytologyHPV genotypeAbnormal cytology% (*N* = 84)HPV 162428.6%HPV 181517.9%HPV 311315.5%HPV 3311.2%HPV 351821.4%HPV 391315.5%HPV 45910.7%HPV 511821.4%HPV 522631.0%HPV 532125.0%HPV 561315.5%HPV 5844.8%HPV 591720.2%HPV 66910.7%HPV 6844.8%Table 5most prevalent pairing occurrences in women with abnormal cytologyPrevalent pairings in abnormal cytology in HIV-negative women: *N* = 35)(*n* = in normal cytology)*n* = abnormal cytology HPV 18 and 3123 HPV 31 and 5272Prevalent pairings in HIV infected women with abnormal cytology: *N* = 52) HPV 16 and 3926 HPV 16 and 5297 HPV 16 and 5145 HPV 16 and 53107 HPV 18 and 52125 HPV 18 and 5385 HPV 31 and 5125 HPV 35 and 5125 HPV 35 and 5347 HPV 45 and 5306 HPV 45 and 5925 HPV 51 and 5327 HPV 51 and 5616 HPV 52 and 5636 HPV 53 and 5615Table 6association between STI, specific pHR/HR HPV genotypes and abnormal cytology; OR fromSTI or HPV genotypeOR Model 1 (95%CI)*p*-valueOR Model 2 (95%CI)*p*-valueBV0.9 (0.6--1.5)0.80.8 (0.5--1.4)0.5TV24.8 (12.7--48.3)\< 0.00130.0 (14.1--62.9)\< 0.001Candida spp1.0 (0.5--1.7)1.00.9 (0.5--1.7)0.7Multiple HPV infection5.3 (2.9--9.7)\< 0.0013.7 (1.9--7.3)\< 0.001HPV 161.9 (0.8--4.5)0.11.2 (0.5--3.2)0.5HPV 180.8 (0.3--2.1)0.71.04 (0.4--2.8)0.9HPV 310.5 (0.2--1.5)0.20.6 (0.2--1.7)0.3HPV 333.9 (0.05--293.9)0.52.8 (0.03--254.6)0.6HPV 351.3 (0.6--3.0)0.51.1 (0.5--2.7)0.9HPV 393.3 (1.3--8.7)0.032.5 (0.9--7.1)0.09HPV 513.7 (1.6--8.6)0.0023.7 (1.5--9.0)0.004HPV 526.1 (2.8--13.3)\< 0.0014.0 (1.6--8.2)0.002HPV 532.0 (0.8--4.9)0.11.4; (0.5--3.8)0.5HPV 562.5 (1.0--6.6)0.062.0 (0.7--5.7)0.2HPV 580.9 (0.2--3.6)0.91.1 (0.3--5.2)0.9HPV 661.2 (0.5--3.0)0.71.0 (0.4--3.0)0.9HPV 681.7 (0.2--17.0)0.70.8 (0.1--7.4)0.8Logistic regression; *p*-value from LRTModel 1: OR adjusting for age, pHR/HR HPV genotypes, STIsModel 2: OR adjusting for age and pHR/HR genotypes, STIs and HIV
